Medicine & Health

School of Medicine researchers have shown how brain tumors evolve in response to therapy, helping describe how such cancers develop treatment resistance that leads to the high mortality rate characteristic of this cancer.

Two studies from Washington University School of Medicine in St. Louis focused on breast cancer and pancreatic cancer suggest that specific types of senescent cells — cells that have stopped dividing and drive inflammation — may play important roles in suppressing the immune system and allowing such tumors to grow unchecked.

Hematologist Amy Zhou, MD, an associate professor at the School of Medicine, values the connections she makes with patients. She is also pursuing research to improve blood cancer treatments.

John F. DiPersio, MD, PhD, the Virginia E. and Sam J. Golman Endowed Professor of Medicine at Washington University School of Medicine in St. Louis, has received the Chancellor’s Award for Innovation and Entrepreneurship for his research contributions.

Researchers at Washington University School of Medicine in St. Louis have found that a strain of gut bacteria can boost immune responses and enhance cancer immunotherapy to fight sarcoma tumors in mice.

A study from biologists and clinicians at Washington University in St. Louis reports that glioblastoma cells have built-in circadian rhythms that create better times of day for treatment.

Researchers at the School of Medicine have received a $5 million grant from the Leukemia & Lymphoma Society to support research aimed at developing new immunotherapies for different types of blood-based cancers.

Sana D. Karam, MD, PhD, a renowned radiation oncologist widely known for cutting-edge cancer research that combines radiation therapy and immunotherapy to treat head and neck, and pancreatic tumors, has been named the James S. McDonnell Professor of Radiation Oncology and head of the Department of Radiation Oncology at the School of Medicine.

Researchers at Washington University School of Medicine have discovered that an FDA-approved epilepsy drug can prevent or slow the growth of NF1-linked optic gliomas in mice, laying the groundwork for a clinical trial.

In a recent study, researchers at Washington University School of Medicine in St. Louis and Whiterabbit.ai showed that artificial intelligence assistance potentially could improve breast-cancer screening by reducing the number of false positives without missing true positives.